Pramod Thomas is a senior correspondent with Asian Media Group since 2020, bringing 19 years of journalism experience across business, politics, sports, communities, and international relations. His career spans both traditional and digital media platforms, with eight years specifically focused on digital journalism. This blend of experience positions him well to navigate the evolving media landscape and deliver content across various formats. He has worked with national and international media organisations, giving him a broad perspective on global news trends and reporting standards.
PROSPECTIVE investors in Life Insurance Corp of India's (LIC) $8 billion IPO are seeking assurances from company management that it will not sacrifice their interests to meet the goals set out by the government, its controlling shareholder, sources said.
In virtual roadshows for India's biggest-ever public listing, LIC management and the IPO bankers have been peppered with questions about the insurer's past investments and their quality, four people with knowledge of the matter said.
LIC has in recent years been a key buyer of shares in state-owned firms sold off by New Delhi, often bailing out less-than-successful public issues of shares. It has also been tapped to rescue struggling financial institutions.
Potential conflicts of interest issues are taking centre-stage in the IPO roadshows that began last week and are expected to go on till the end of the month, the sources said.
"The government tends to act as a regulator, manager and shareholder and it tends to get its position confused at different points of time," said Shriram Subramanian, founder of proxy advisory firm InGovern, who has not attended the roadshows.
"The government ministries may tend to think that LIC is 100 per cent under their control and would like to exert that kind of an influence whenever required and that is a concern for investors," Subramanian added.
How effectively LIC and its investment bankers are able to address the investor concerns will help in determining the insurer's valuation in the float, and consequently the state of finances of the Indian government which is banking on proceeds from the IPO to plug an annual fiscal deficit hole.
The Finance Ministry did not respond to emails seeking comment while LIC declined. The sources declined to be identified as the discussions are private.
In its draft prospectus, the insurer cited the involvement of the government, which owns 100 per cent of LIC now and is expected to own about 95% after the IPO, as a risk factor and said that minority shareholders could be disadvantaged by government action.
LIC chairman M R Kumar told a news conference on Monday (21) that potential investors should not worry about government control post the IPO as decisions are taken by its board and not by the government.
LIC-a big investor
LIC, which was formed six decades ago when India's insurance sector was nationalised, straddles the business in the country, with more than 280 million policies and over 60 per cent of the insurance segment.
It is also a big investor, owning as of March last year $315bn worth of government securities, higher than even the central bank, out of the total central and state government securities worth $15,413bn, according to the prospectus.
In 2019, it took over troubled IDBI Bank as the government struggled to find a viable buyer for the lender whose shares had tanked and nearly a third of its book had gone bad.
LIC said in its draft papers that it may have to infuse more capital into IDBI Bank even though it has been pursuing a buyer for its more than 50 per cent stake in the lender.
Some market analysts and fund managers are drawing parallels of LIC with Coal India, which made its market debut in 2010 and, despite being a monopoly, has lost over half its equity value.
"If LIC makes decisions that are not beneficial for the shareholders then they will raise concerns," said Ashvin Parekh, an independent financial services consultant.
"We have seen that happen earlier when Children Investment Fund exited from state-owned Coal India after listing as it had concerns over what the majority shareholder was doing and LIC could also face similar pushbacks from its shareholders."
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.